Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction-Reference-Cited by-同舟云学术

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Published:2015-02 Issue:2 Volume:27 Page:240-256
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Moriceau Gatien,Hugo Willy,Hong Aayoung,Shi Hubing,Kong Xiangju,Yu Clarissa C.,Koya Richard C.,Samatar Ahmed A.,Khanlou Negar,Braun Jonathan,Ruchalski Kathleen,Seifert Heike,Larkin James,Dahlman Kimberly B.,Johnson Douglas B.,Algazi Alain,Sosman Jeffrey A.,Ribas Antoni,Lo Roger S.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference22 articles.

1. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010

2. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK;Brennan;Nature,2011

3. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal;Catalanotti;Nat. Struct. Mol. Biol.,2009

4. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation;Corcoran;Sci. Signal.,2010

5. MEK1 mutations confer resistance to MEK and B-RAF inhibition;Emery;Proc. Natl. Acad. Sci. USA,2009

Cited by 285 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy;Cell;2024-09

3. CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers;2024-07-29

4. Role of Annexin 7 (ANXA7) as a tumor suppressor and a regulator of drug resistance in thyroid cancer;2024-05-20

5. RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition;Molecular Cancer;2024-05-16